Rezolute, Inc.

Contributing Author

Recent Articles by Rezolute, Inc.

May-12	Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update RZLT GlobeNewswire
May-11	Rezolute to Participate in Upcoming Investor Conferences RZLT GlobeNewswire
May-01	Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting RZLT GlobeNewswire
Apr-21	Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting RZLT GlobeNewswire
Mar-24	Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting RZLT +12.08% GlobeNewswire
Mar-04	Rezolute to Participate in the Citizens Life Sciences Conference RZLT +6.15% GlobeNewswire
Feb-12	Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update RZLT +7.72% RZLT +5.79% GlobeNewswire
Feb-04	Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 RZLT -7.62% GlobeNewswire
Jan-07	Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism RZLT +23.04% GlobeNewswire
Dec-11	Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism RZLT -87.20% GlobeNewswire
Nov-10	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RZLT -7.48% GlobeNewswire
Nov-06	Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update RZLT +12.08% RZLT GlobeNewswire
Nov-05	Rezolute to Host Virtual Investor Event on Ersodetug Development Program RZLT +5.06% GlobeNewswire
Oct-15	Rezolute to Participate in Upcoming Investor Conferences RZLT +6.89% GlobeNewswire
Oct-09	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RZLT -6.34% RZLT GlobeNewswire
Sep-17	Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update RZLT +6.36% RZLT GlobeNewswire
Sep-02	Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism RZLT GlobeNewswire
Aug-27	Rezolute to Participate in Upcoming Investor Conferences RZLT GlobeNewswire
Aug-20	Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer RZLT GlobeNewswire
Jul-22	Rezolute to Participate in the BTIG Virtual Biotechnology Conference RZLT GlobeNewswire
Jul-09	Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) RZLT +6.24% GlobeNewswire
May-28	Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism RZLT GlobeNewswire
May-13	Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update RZLT GlobeNewswire
May-05	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism RZLT GlobeNewswire
May-01	Rezolute to Participate in Upcoming Investor Conferences RZLT +5.32% GlobeNewswire

Rezolute, Inc.

Recent Articles by Rezolute, Inc.

Upgrade your Finviz experience